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ABSTRACT
In the human prostate, expression of prostate-
specific genes is known to be directly regulated by
the androgen–induced stimulation of the androgen
receptor (AR). However, less is known about the
expression control of the prostate-restricted TGM4
(hTGP) gene. In the present study we demonstrate
that the regulation of the hTGP gene depends mainly
on retinoic acid (RA). We provide evidence that
the retinoic acid receptor gamma (RAR-G) plays a
major role in the regulation of the hTGP gene and
that presence of the AR, but not its transcriptional
transactivation activity, is critical for hTGP tran-
scription. RA and androgen responsive elements
(RARE and ARE) were mapped to the hTGP
promoter by chromatin immunoprecipitation
(ChIP), which also indicated that the active ARE
and RARE sites were adjacent, suggesting that the
antagonistic effect of androgen and RA is related
to the relative position of binding sites. Publicly
available AR and RAR ChIP-seq data was used to
find gene potentially regulated by AR and RAR.
Four of these genes (CDCA7L, CDK6, BTG1 and
SAMD3) were tested for RAR and AR binding
and two of them (CDCA7L and CDK6) proved to be
antagonistically regulated by androgens and RA
confirming that this regulation is not particular of
hTGP.
INTRODUCTION
Retinoic acid (RA) is a molecule with a wide variety of
biological functions. In vertebrates, RA is known to
control the differentiation process by altering the gene
expression proﬁle of cells (1). For example, RA partici-
pates in the transcriptional regulation of the Hox gene
clusters (2,3), which are key to the development process
in vertebrate and invertebrate organisms (4,5). RA is able
to modify gene expression by activation of a family of
non-steroid nuclear receptors known as retinoic acid
receptors (RARs) and retinoid x receptors (RXRs),
which function as heterodimeric units (6) and bind to
the retinoic acid responsive elements (RAREs) present in
the promoters or DNA regulatory elements of target
genes, thus regulating their expression (7,8). Activated
RARs are therefore responsible for promoting not only
differentiation but also cell-cycle arrest and apoptosis
(9–12), among other effects.
In prostate development and morphogenesis, androgens
play a major role, for example in the stimulation of the
mesenchyme to induce prostate formation and prostate
secretory function (13,14). However, androgens are not
the only molecule to regulate prostatic development.
Retinoic acid controls both the proliferation and differen-
tiation of prostate epithelium (15,16). To underline the
importance of RA signalling in both prostate development
and function, transgenic mice lacking RAR-G develop
prostate squamous metaplasia (17) which also renders
them sterile.
In different organs, tissue-speciﬁc gene expression is
controlled by discrete sets of transcription factors and
epigenetic mechanisms (18,19). In the prostate for
example, most tissue speciﬁc expression is mediated by
androgens, and modulated by the nuclear receptor for
androgen (AR). Classical prostate speciﬁc genes such as
KLK3 (PSA), FOLH1 (PSMA), NKX3.1 and TARP
have all been shown to be directly regulated by
androgen (20–24). Because of the role of androgen and
the AR in prostate maintenance and development, it is
usually assumed that classical androgen regulation is
obligatory for prostate speciﬁc expression.
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(hTGP) stands out as one of the most prostate speciﬁc
genes reported to date (21). hTGP has been mapped to
chromosome 3 in humans (21). Its function in rodents is
related to fertilization and reduction of sperm antigenicity
(25–27), while in humans hTGP expression has been
linked to the invasive potential of prostate cancer cells
(28). In vitro, hTGP transcription is controlled by
androgen but only after extended treatment experiments
in PC346C, but not in LNCaP prostate cancer cells,
despite the presence of active AR in both cell lines.
Promoter analysis also showed that the presence of an
SP1-binding site in the proximal hTGP promoter region
was needed for optimal expression, however no classical
androgen control or functional androgen responsive
elements (AREs) were found in the minimal promoter
sequence (21,29).
Despite its critical role in prostate development, growth
and differentiation, examples of the importance of retinoic
acid in adult prostate gene expression are scarce; NKX3.1
is the only case of a prostate speciﬁc gene whose expres-
sion, while mainly regulated by androgen, can be affected
by retinoic acid (30,31).
This work describes the ﬁrst report of a prostate speciﬁc
gene where androgen regulation plays a minor and
negative role, and where RA is the main regulator of
hTGP expression in prostate cancer cell lines. It provides
evidence that other mechanisms apart from classical
androgen–AR transcriptional control, regulate the expres-
sion of this highly prostate speciﬁc gene. It also implies
that AR/RAR antagonistic effects are a widespread mech-
anism to regulate transcription within the prostate gland.
These ﬁndings cast doubts on the primacy of classical
androgen–AR regulation for prostate speciﬁc expression
and expose the potential importance of RA not only in
prostate development but also, in maintaining glandular
homeostasis.
MATERIALS AND METHODS
Cell culture and treatments
LNCaP (ATCC), PNT1A and PNT2C2 cells (32) were
grown in RPMI-1640 media (GIBCO) supplemented
with 10% FCS (PAA Laboratories) and 2mM
L-Glutamine (Invitrogen). PC346C cells were maintained
in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)
(GIBCO)/Ham’s F12 (Lonza) supplemented with 100mg/
ml streptomycin, 100U/ml penicillin G, 2% FCS, 0.01%
(w/v) BSA, 10ng/ml EGF, 1% (v/v) ITS-G, 0.1nM
R1881, 1.4mM hydrocortisone, 1nM triiodothyronine,
0.1mM phosphoethanolamine, 50ng/ml cholera toxin
(Sigma), 0.1mg/ml ﬁbronectin and 20mg/ml fetuin. All
cells were certiﬁed free of mycoplasma and genotyped
(using the ATCC-approved Powerplex 1.2 system
(Promega) to ensure authenticity. Cells were routinely
passaged in T25 ﬂasks at 37 C with 5% CO2.
In advance of atRA (Sigma), R1881 (DuPont),
Bicalutamide (Sigma) or TTNPB (Sigma) treatments,
cells were grown for 24h in charcoal stripped serum
supplemented media.
Gene expression proﬁle in human tissues
TissueScan Human Normal Tissue qPCR Arrays
(OriGene Technologies, Rockville MD) were used to
screen for hTGP, PSA and TMPRSS2 expression in 48
different tissues using Taqman gene expression assays
Hs00162710_m1, Hs02576345_m1 and Hs01120965_m1
and following manufacturer’s instructions.
Gene expression
Total RNA was puriﬁed using the RNeasy mini Kit
(Qiagen) following manufacturer’s protocol. cDNA was
synthesize using Suprescript II enzyme (Invitrogen) and
random primers (Invitrogen) following manufacturer’s
protocol. qPCR experiments were carried out using
50ng cDNA as template, the Power SYBR Green PCR
master mix and speciﬁc primer pairs. RT–PCR experi-
ments were performed in a GeneAmp PCR system 9700
thermocycler (Applied Biosystems) using Platinum taq
DNA polymerase (Invitrogen), 10ng of cDNA as
template following manufacturers protocol (for primer
sequences see Supplementary Table S3).
Western blot analysis
Whole cell lysate or nuclear proteins were isolated using
Cytobuster reagent (Novagen) or the Nuclear and
Cytoplasmic Extraction Kit (Pierce) following manufac-
turer’s protocol. Antibodies used were anti-pan RAR
(sc-773) anti-RAR-B (sc-552), anti-RAR-G (sc-550),
anti-AR (sc-816) from Santa Cruz Biotechnologies, anti
B-actin (A5316) from Sigma and anti-TBP (1TBP18)
from Abcam.
Generation of hTGP promoter constructs and mutants
hTGP promoter sequence (4.5kb) was ampliﬁed using the
Expand High Fidelity PCR system (Roche) using speciﬁc
primers (Supplementary Table S3) and the manufacturer’s
protocol and cloned into the pEGFP-1 plasmid (Clontech)
using the restriction enzymes XhoI and SacII. To clone the
hTGp (4.5kb) and the several deletion mutants into the
pGL3 basic vector (Promega), the In Fusion cloning
system was used (Clontech) following manufacturer’s
protocol (see Supplementary Table S3 for primers
sequence) and transformed into STBL3 (Invitrogen)
chemically competent Escherichia coli. All sections of the
promoter that involved PCR ampliﬁcation were subject to
DNA sequencing to conﬁrm the ﬁdelity of the ampliﬁca-
tion. For the generation of constructs with mutated
RAREs and ARE, the QuikChange II XL kit
(Stratagene) was used following manufacturer’s
instructions.
Plasmid transfection and luciferase assay
Cells were seeded in 96-well plates and grown for 24h in
charcoal stripped media previous to transfection. To
measure retinoic acid responsiveness, Cignal RARE
reporter (luc) kit plasmids (CCS-016L) from
SABiosciences were transfected into LNCaP, PC346C,
PNT1A and PNT2C2 cells using TransIT-LT1 for
PC346C, PNT1A and PNT2C2 and TransIT-2020 for
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turer’s protocol. For the functional analysis of the hTGp
promoter, plasmid mixtures containing the different
versions of the hTGP promoter and the pRL-CMV
Vector (Promega) (in a 1:1 copy number ratio) were
co-transfected into LNCaP cells grown for 24h in
charcoal stripped media, using TransIT-2020 as a trans-
fection reagent. Twelve hours after transfection cells were
treated either with atRA or R1881 for further 24h.
Luciferase expression was measured using the Dual-Glo
system (Promega) following manufacturer’s protocol
using the Polarstar Optima micro-plate reader (BMG).
siRNA knockdown
LNCaP cells were grown in six-well plates coated with
L-Polylysine and transfected with Silencer select (Applied
Biosystems) siRNAs targeting RAR-B (siRNA ID:
s11804), RAR-G (siRNA ID: s11807), AR (siRNA ID:
s1538) or Negative control ]i using DharmaFECT 2
(Dharmacon) as transfection reagent.
Immunoﬂuorescence
PC346C or LNCaP cells were seeded in Poly-D-Lysine
eight-well CultureSlides (BD) in charcoal stripped media
for 48h. Before ﬁxation, cells were brieﬂy washed with
PBS, ﬁxed by adding cold methanol ( 20 C) for 5min,
then air-dried. Incubation in 10% goat serum (Sigma) for
1h was used to block non-speciﬁc antibody binding. Cells
were incubated with AR antibody (sc-816) or IgG rabbit
isotype (Sigma) as negative control in 1% BSA/PBS for
1h at room temperature. Secondary antibody goat
anti-rabbit labelled with Alexa Fluor 488 (Invitrogen)
was incubated for 30min in 1% BSA/PBS at room
temperature. Slides were mounted with VECTASHIELD
with DAPI (Vector Laboratories).
Chromatin immunoprecipitation
Cells were grown in T175 ﬂasks in charcoal stripped media
for 24h, then treated with either, atRA (500nM), R1881
(10nM) or vehicle (DMSO) for 10h. After treatments
cells were trypsinized and re-suspended in 5ml media
and treated with formaldehyde to a ﬁnal concentration
of 1% for 10min at room temperature with gentle
shaking. Glycine was added to stop ﬁxation to a ﬁnal
concentration of 0.125M for 5min at room temperature.
Cells were washed with cold PBS and re-suspended in cold
swelling buffer (5mM Pipes pH 8, 85mM KCl) supple-
mented with NP-40 (ﬁnal concentration of 0.2%)
and protease inhibitors (Roche). The cell suspension was
incubated in ice with gentle shaking for 20min.
Suspension was centrifuged at 3000rpm and resuspended
in IP buffer TSE150 (0.1% SDS, 1% Triton, 2mM
EDTA, 20mM Tris–HCl pH 8, 150mM NaCl) supple-
mented with protease inhibitors (Roche) and sonicated
using a Bandelin Sonopuls HD 2070, for 21 cycles of
30s on/30s off at full power. Chromatin was centrifuged
at 14000rpm for 30min, aliquoted and stored at  80 C.
A sample of the sonicated chromatin was puriﬁed using a
phenol/chloroform extraction to corroborate correct
chromatin disruption. Protein A-sepharose beads
(Sigma) were blocked by incubating them in an IP
buffer TSE150 solution containing yeast tRNA (Sigma)
to a ﬁnal concentration of 1mg/ml and BSA (Sigma) to
a ﬁnal concentration of 250mg/ml while rotating at 4 C
for 4h. Chromatin was cleaned-up by incubating 50mlo f
50% pre-blocked protein A-sepharose beads with 20mg/IP
of chromatin in a total volume of 1ml TSE 150 buffer for
1.5h at 4 C while rotating. The suspension was
centrifuged for 1min at 3000rpm and supernatant kept
in a separate tube. An amount of 20ml of the supernatant
were kept to be used as INPUT control, then the rest was
divided and incubated with either anti-RAR (sc-773),
AR (sc-816) (Santa Cruz Biotech) or puriﬁed rabbit IgG
(PP64B Millipore) at 4 C overnight. Antibody–protein–
DNA complexes were recovered by incubation with 50ml
of 50% pre-blocked protein A sepharose beads for 1.5h at
4 C. Beads were retrieved by centrifugation at 3000rpm
for 1min at room temperature and washed with IP buffer
TSE150, IP buffer TSE500 (0.1% SDS, 1% Triton, 2mM
EDTA, 20mM Tris–HCl pH 8, 500mM NaCl), washing
buffer (10mM Tris–HCl pH 8, 0.25M LiCl, 0.5% NP-40)
and TE buffer (10mM Tris–HCl pH 8, 1mM EDTA).
DNA was eluted by adding 100ml of elution buffer (1%
SDS, 10mM EDTA, 50mM Tris–HCl pH 8) and a incu-
bation step at 65 C for 15min. Beads were centrifuged
at 15000rpm for 1min and supernatant transferred to a
separate tube. Beads were rinsed with 150ml TE/1% SDS,
vortexed, centrifuged at 15000rpm and supernatant
pooled with previous one. Immunoprecipitated DNA
was left at 65 C overnight, then treated with proteinase
K (Invitrogen) and added glycogen (Roche) for 2h.
DNA was puriﬁed by phenol/chloroform extraction.
Bioinformatic analyses
AR-binding sites and microarray data. Time series micro-
array data autocorrelation from (33) (Supplementary
Table S1) were used to select probes showing signiﬁcant
(autocorrelation 0.5) androgen-mediated expression al-
teration (GEO GSE18684). Probes were annotated to
genes using the Bioconductor Illumia human BeadArray
mappings (34) against the UCSC human reference genome
hg18. Genes were assigned unique ENTREZ identiﬁers
for comparison with other datasets.
Chromatin immunoprecipitation(ChIP)-seq data for
both LNCaP and VCaP cell lines was downloaded from
the same source. Peak positions for both datasets were
mapped to unique ENTREZ identiﬁers based upon
proximity to gene start sites. Data from both the
LNCaP and VCaP cell lines were combined for down-
stream analysis.
RARA ChIP-Seq data. ChIP-seq data for RAR-alpha
was obtained from (35), SRA study accession number
SRA010193. Peak positions for both datasets were
mapped to unique ENTREZ identiﬁers based upon
proximity to gene start sites.
RARA and RARG ChIP–chip data. ChIP–chip data for
both RAR-alpha and RAR-gamma was obtained from
(36) (Supplementary Table S2), GEO database under
GSE15244.
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ENTREZ identiﬁers based upon proximity to gene
start sites.
Combined dataset analysis
Combined AR ChIP–chip data was created by ﬁnding
the genes present in both the ChIP-seq and expression
microarray datasets from (33). Combined RAR data was
created using the intersection between the datasets
determined from (35) and (36).
Distance analysis
Genes in both of the two gene sets were tested for the
frequency and distance between AR-binding sites and
putative RAR sites. All possible pairs of AR site and
RAR site in each gene were checked for the distance
between the sites. The number of distances less than
500 bases were recorded.
RESULTS
hTGP is a highly prostate speciﬁc gene
To assess with a quantitative method, such as qPCR, the
extent to which hTGP gene expression is prostate-speciﬁc,
its expression proﬁle was compared to that of PSA
and TMPRSS2 genes, which are regarded as prostate
speciﬁc, in a qPCR array containing cDNA from 48 dif-
ferent normal human tissues. hTGP expression was
 200-fold higher in prostate in comparison to the next
highly expressing tissue (testis). PSA also showed a
highly prostate-speciﬁc proﬁle. Expression levels were
>400-fold enriched in the prostate, in comparison to the
second highest expressing (adipose) tissue. In comparison,
TMPRSS2 showed higher expression in the prostate but
the fold enrichment was just 1.55-fold, while lungs and
stomach also showed high expression (Figure 1). The
number of tissues, apart from prostate, where expression
could be detected showed that hTGP expression
(21 tissues) was more restricted to the prostate than both
PSA (32 tissues) and TMPRSS2 (39 tissues) (Figure 1).
Figure 1. hTGP expression is highly prostate speciﬁc. hTGP, KLK3 and TMPRSS2 expression was analysed by qPCR using speciﬁc taqman probes
and arrays containing cDNA from 48 different human tissues. Expression is shown relative to the second highest absolute value.
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LNCaP and PC346C is regulated by atRA
Previous studies indicated that hTGP expression was
controlled by androgen over long periods of androgen
exposure (7–10 days) (21), but paradoxically no AREs
could be found in a 2.1-kb region of the proximal
promoter (29) which suggests an indirect androgen
regulation of the hTGP gene. Bioinformatic re-analysis
of a longer section of the hTGP promoter indicated the
presence of a H3K4me2 region between  4898 and
 3698. H3K4me2 is a histone mark associated with the
presence of enhancers or transcription start sites (37,38).
Since this was the only region within the hTGP promoter
and gene with this feature, it was decided to ﬁnd putative
binding sites for transcription factors within this 5.5-kb
upstream of the hTGP transcriptional start site.
Bioinformatic analysis located not only AREs but also
RAREs (Figure 2A). In the light of these results, it was
decided to re-examine the effects of both hormones on
hTGP expression in cell lines from normal and malignant
prostate. First, to explore RA regulation, the prostate cell
lines LNCaP, PC346C, PNT1A and PNT2C2 were treated
with 500nM all-trans retinoic acid (atRA), which is within
the range of commonly used atRA concentrations
(35,39,40), for 24h to test whether this compound could
regulate hTGP expression. LNCaP and PC346C are
prostate cancer cell lines with luminal characteristics;
they express PSA, AR and are responsive to androgen.
PNT1A and PNT2C2 are benign prostate cell lines less
differentiated than LNCaP and PC346C. PNT1A and
PNT2C2 do not express AR and are not affected by the
presence or absence of androgens (41). While LNCaP and
PC346C cells treated with atRA showed a marked increase
in hTGP expression, the normal, less-differentiated
PNT1A and PNT2C2 cells showed a small decrease
(Figure 2B). As the difference in hTGP regulation after
atRA treatment could be the result of differential RAR
expression in the different cell lines, total RAR protein
and mRNA was measured in LNCaP, PC346C, PNT1A
and PNT2C2 cells. PNT1A and PNT2C2 showed higher
levels of total RAR protein in comparison to LNCaP and
PC346C while mRNA for the different RARs did not
show a clear tendency that could explain the lack of
hTGP up-regulation after atRA treatment in PNT1A
and PNT2C2 cells (Figure 2C and D). To functionally
test the extent to which each cell line could sustain
atRA-dependent gene activation, the cells were
co-transfected with a reporter plasmid containing a
tandem of RAREs controlling the expression of the
ﬁreﬂy luciferase gene and a control construct where the
CMV promoter controlled expression of the Renilla
luciferase gene. Twenty-four hours after transfection
cells were treated with increasing concentrations of
atRA and luciferase activity was measured after a
further 18h. The results showed that LNCaP and
PC346C cells could sustain atRA-dependent gene expres-
sion to a higher extent (up to 10.6- and 17.9-fold increase
respectively) in comparison to PNT1A and PNT2C2
cells (up to 5.4- and 4.53-fold increase respectively)
(Figure 2E). The greater extent to which LNCaP and
PC346C sustain atRA-dependent transcription explains
the lack of hTGP up-regulation observed in PNT1A and
PNT2C2 cells.
Androgen has a minor and negative role in hTGP
regulation
Next, to test whether androgen affects hTGP expression
within a more physiological 24h treatment period than in
the previous studies, LNCaP and PC346C cells were
treated with increasing concentrations of the syn-
thetic androgen R1881. Surprisingly, hTGP expression
decreased slightly after R1881 treatments in LNCaP,
while in PC346C, hTGP expression decreased signiﬁcantly
down to 0.65-fold (P<0.05) in cells treated with 0.1, 1 and
10nM R1881 (Figure 3A). LNCaP and PC346C cells were
treated with R1881 0.1 or 10nM and/or atRA 500nM for
24h to assess whether the effects of R1881 and atRA were
antagonistic. LNCaP and PC346C cells treated with atRA
or R1881 showed an increase and decrease of hTGP
expression respectively and co-treatment with 0.1nM
R1881 and 500nM atRA decreased atRA-dependent
hTGP expression in LNCaP but not in PC346C cells
(Figure 3B, left panel). However co-treatment of 10nM
R1881 and 500nM atRA resulted in complete abrogation
of atRA-induced hTGP expression in LNCaP and a small
decrease in PC346C cells (Figure 3B, right panel). To test
whether AR knockdown could rescue R1881-dependent
hTGP down-regulation, LNCaP cells were transfected
with siRNA targeting the AR. AR was successfully
knocked-down and mRNA levels remained low even
24h after R1881 treatment (Figure 3C). Surprisingly,
AR knockdown not only failed to rescue hTGP
down-regulation after R1881 treatment but also had a
signiﬁcant (P<0.05) negative effect on basal hTGP
expression (Figure 3D).
AR presence but not its transactivational activity regulate
hTGp expression
AR knockdown had a negative effect on atRA-dependent
hTGP expression, when LNCaP cells were transfected
with AR-speciﬁc siRNA, both in untreated conditions
and 24h after atRA treatment (500nM) (Figure 4A). To
evaluate if AR knockdown was down-regulating RAR
levels and therefore acting to decrease hTGP expression,
RAR-A, RAR-B and RAR-G mRNA levels in AR
knockdown LNCaP cells were measured. AR knockdown
up-regulated RAR-A and RAR-G levels but had no effect
on RAR-B mRNA expression (Figure 4B). Next, LNCaP
cells were treated with the AR inhibitor bicalutamide,
which inhibits the receptor’s ability to recruit co-activators
without affecting its DNA-binding ability, (42) to investi-
gate if the AR knockdown effect was caused by the loss of
AR transactivation. As expected, bicalutamide treatments
had a negative effect on PSA transcription (a canonical
AR responsive gene) even after R1881 treatment, conﬁrm-
ing the block in AR activity (Figure 4C). Moreover,
in LNCaP cells treated with atRA and bicalutamide,
hTGp expression remained unchanged, suggesting that
direct AR transcriptional activity did not affect hTGP
expression. Although it has been reported that the AR is
Nucleic Acids Research, 2012,Vol.40, No. 11 4829Figure 2. hTGP expression is up-regulated by retinoic acid. (A) Schematic representation of a 4.5-kb hTGp promoter showing putative AREs and
retinoic acid responsive elements (RARE). (B) hTGp relative expression in LNCaP, PC346C, PNT1A and PNT2C2 cells treated with vehicle or atRA
(500nM) for 24h. Statistically signiﬁcant T-test differences are denoted with the asterisk symbol (P<0.05) (C) RAR protein expression in LNCaP,
PC346C, PNT1A and PNT2C2 whole cell lysates, B-actin was used as a loading control. (D) mRNA expression of RAR-A, RAR-B and RAR-G in
LNCaP, PC346C, PNT1A and PNT2C2 cells. (E) atRA responsiveness of each cell line was measured by co-transfecting a reporter plasmid where the
ﬁreﬂy luciferase gene is under the control of a tandem of RAREs and a reporter plasmid where the Renilla luciferase expression is controlled by the
constitutive CMV promoter. The negative control consisted in the same luciferase reporter gene construct as the test plasmid but lacking the RAREs
elements. After transfection cells were treated with increasing concentrations of atRA for 18h and luciferase activity was measured. All ﬁreﬂy
luciferase values were normalized against Renilla luciferase expression.
4830 Nucleic Acids Research, 2012,Vol.40, No. 11Figure 3. Androgen has a minor and negative effect on hTGP mRNA expression while AR knockdown has a negative effect on its expression.
(A) Relative hTGp mRNA expression, in LNCaP and PC346C cells treated with vehicle or increasing concentrations of the synthetic androgen
R1881. (B) RT–PCR detection of hTGp, PSA and GAPDH in LNCaP and PC346C cells treated with atRA (500nM), androgen (0.1 or 10nM) or a
combination for 24h. (C) AR mRNA (left) and protein knockdown (right) in LNCaP cells. (D) hTGp mRNA expression in LNCaP cells after AR
knockdown with or without R1881 treatment for 24h. Statistically signiﬁcant t-test differences are denoted with the asterisk symbol (P<0.05).
**Note the lower molecular weight band in the hTGP RT–PCR ampliﬁcation is a known splice variant.
Nucleic Acids Research, 2012,Vol.40, No. 11 4831unable to bind atRA (43), we further conﬁrmed this by
immunostaining for the AR in LNCaP and PC346C
cells treated with 10nM R1881 or 500nM atRA for 2h.
AR localization is both nuclear and cytoplasmic in
LNCaP and PC346C cells in the absence of treatment
(Figure 4D, left panels). Upon R1881 addition almost
all of the detectable AR translocates into the nucleus
(Figure 4D, middle panels). In atRA-treated cells the
AR was present in both cytoplasm and nucleus in a
similar pattern to that in untreated cells (Figure 4D,
Figure 4. AR is important for hTGP expression. (A) hTGP mRNA expression in AR knockdown LNCaP cells treated with vehicle or atRA
(500nM) for 24h. (B) RAR-A, RAR-B and RAR-G mRNA expression in AR knockdown LNCaP cells. (C) PSA (left panel) and hTGP (right
panel) mRNA expression in LNCaP cells treated with vehicle, bicalutamide (5mM), R1881 (10nM), atRA (500nM) or a combination for 24h.
(D) Left panel: AR immunoﬂuorescence in LNCaP cells 2h after R1881 (10nM) and atRA (500nM), bars are equivalent to 20mm. Negative control
for immunoﬂuorescense (IgG isotype and secondary antibody alone) are shown in the right panel. Statistically signiﬁcant t-test differences are
denoted with the asterisk symbol (P<0.05).
4832 Nucleic Acids Research, 2012,Vol.40, No. 11right panels). Thus atRA did not affect the intracellular
location of AR and did not activate this receptor.
RAR-G has a major role in atRA-dependent hTGp
expression
To determine whether the hTGP gene could be controlled
by the RARs, LNCaP and PC346C cells were treated for
24h with 250 or 500nM of the synthetic retinoid 4-[(E)-2-
(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-
1-propenyl]-benzoic acid (TTNPB), which selectively
binds to the RARs and induces transcription of its
target genes (40,44). Both TTNPB concentrations
enhanced hTGP expression, suggesting that the hTGP
gene can be directly controlled by the RARs
(Figure 5A). Among the RARs, RAR-B and RAR-G
seem to play a major role in prostate biology. RAR-B
and RAR-G are expressed in the rat prostate at an early
stage; RAR-G deﬁcient mice show prostate malforma-
tions and RAR-B is often down-regulated in prostate
cancer (17,45,46) making these genes obvious candidates
to control hTGP expression. Therefore, LNCaP cells were
transfected with speciﬁc siRNA targeting either RAR-B
or RAR-G mRNA, to determine the speciﬁc RAR(s)
responsible for atRA induced hTGP expression. mRNA
and protein knockdown were conﬁrmed (Figure 5B).
RAR-B knockdown had a negative impact on basal
hTGP mRNA levels but had no effect after atRA induc-
tion (Figure 5C, left panel). RAR-G knockdown had a
signiﬁcant (P<0.05) negative effect on basal hTGP
mRNA expression as well as in atRA treated cells
(Figure 5C, right panel), implying that it is RAR-G,
which plays the major role in atRA-dependent hTGP
expression.
Localization of an upstream enhancer element and binding
of the RAR-G and AR to the hTGp promoter
To analyse whether the elements that control atRA
and AR-dependent hTGP regulation were present in the
DNA sequence of the 4.5kb hTGP promoter, the
promoter was cloned, alongside several deletion mutants
(Supplementary Figure S1), into a pGL3 basic luciferase
reporter plasmid. Co-transfection of the different plasmids
containing different lengths of the hTGP promoter and
a construct where the CMV promoter controls the expres-
sion of the Renilla luciferase (as a transfection efﬁciency
control) in LNCaP cells resulted in the detection of
a positive regulatory region or enhancer in the upstream
region of the promoter ( 4500 to  3500 region) which is
active in the absence of any treatment (Supplementary
Figure S1). atRA (500nM) and R1881 (10nM) treatments
up-regulated and down-regulated luciferase expression
respectively only in cells transfected with the full 4.5-kb
hTGP promoter, mimicking the behaviour of the
endogenous gene (Supplementary Figure S1C and D).
ChIP was carried out to map the binding sites of the
RAR and AR, in untreated and in atRA (500nM) or
R1881 (10nM) treated LNCaP cells, using a set of
primers that amplify both regions close to the predicted
location of the RAREs and AREs and regions where there
were no predicted binding sites (Figure 6A). RAR binding
to the hTGP promoter presented the same pattern in
vehicle-treated as well as atRA and R1881 treated cells
(Figure 6B–D). The ChIP RAR-binding sites align
with the predicted RAREs located at  3942 and  1629
(Figure 6B). AR binding to the hTGP promoter showed a
similar pattern to RAR binding in vehicle-treated cells
(Figure 6B), and decreased in atRA treated cells except
for the region  3962 where AR binding was maintained
(Figure 6C). In R1881-treated cells, AR showed a higher
binding in the  3962 region, which is adjacent to
a putative ARE element located at  4094 (Figure 6D).
To test whether the binding enrichment in each region
was signiﬁcant, values were normalized to the IgG
control and tested using Student’s t-test for statistical
signiﬁcance (Supplementary Figure S2).
To further conﬁrm these results, the putative responsive
elements (RAREs and ARE), detected by promoter
analysis and ChIP were next deleted, and the activity of
the hTGP promoter measured following atRA or R1881
treatment. For this purpose the WT 4.5-kb hTGP
promoter was subjected to site-directed mutagenesis,
which deleted between 5 and 7nt of the corresponding
responsive element, in order to alter the binding of
the receptors. The WT construct and the mutants
(Figure 6E) were transfected into LNCaP cells and
treated with 500nM atRA or 10nM R1881 for 24h
before measuring luciferase activity. As in previous experi-
ments, the WT 4.5-kb hTGP construct activated luciferase
expression following atRA treatment, and repressed
luciferase expression after R1881 treatment. However,
the disruption of the 50 RARE (RARE1) resulted in
down-regulation of luciferase expression following
atRA treatment suggesting that the 30 RARE (RARE2),
being the unchanged RARE, had a negative effect on
gene expression following atRA treatment. Disruption of
RARE2, resulted in increased expression in basal condi-
tions, and following atRA treatment, to more than twice
the expression levels in the WT construct. Disruption of
the ARE increased luciferase expression following atRA
treatment. No changes in luciferase down-regulation were
detected following R1881 treatment (Figure 6F), suggest-
ing that either deletion of those particular nucleotides is
not sufﬁcient to alter the binding of the AR to that site or
that the androgen mediated effects on the hTGP are
exerted through other regulatory element that could not
be detected. A model summarising the regulation of
the hTGP gene is illustrated in Supplementary Figure S3.
Opposing effects of AR and RAR are not an hTGP
exclusive mechanism
To investigate whether AR and RAR control the tran-
scriptional regulation of other genes, a bioinformatic
analysis was carried out to compare the occurrence of
AREs and RAREs across the entire human genome
(Supplementary Figure S4). AR–chip-Seq data from a
recent manuscript describing AR-target genes in LNCaP
and VCaP cells (33) was used to identify directly
AR-responsive genes. To identify RAR-target genes,
RAR–chip–Seq and RAR–chip–chip data was then used
from two independent reports (35,36). AR-target genes
Nucleic Acids Research, 2012,Vol.40, No. 11 4833Figure 5. RAR-G plays a major role in atRA-dependent hTGP expression. (A) hTGP mRNA expression in LNCaP and PC346C cells treated with
vehicle or the synthetic retinoid TTNPB for 24h. (B) RAR-B (left panels) and RAR-G (right panels) mRNA and protein knockdown in LNCaP
cells. (C) hTGP mRNA expression in RAR-B (left) and RAR-G (right) knockdown LNCaP cells treated with vehicle or atRA (500nM) for 24h.
Statistically signiﬁcant t-test differences are denoted with the asterisk symbol (P<0.05).
4834 Nucleic Acids Research, 2012,Vol.40, No. 11and RAR-target genes were compared to obtain a list of
candidate genes (Supplementary Table S1), which are
likely to be controlled by both retinoic acid and androgen.
To validate this analysis, RAR and AR ChIP were per-
formed on the predicted binding regions on selected genes.
RAREs and AREs from CDCA7L, CDK6, BTG1 and
SMAD3 were assessed for RAR and AR binding follow-
ing atRA or R1881 treatment. Figure 7 demonstrates that
all candidate genes have bound RAR and AR in their
corresponding RAREs and AREs, following atRA or
R1881 treatment. Since it was found that the role of
atRA and R1881 had opposite effects on the regulation
of hTGP, changes in the expression of CDCA7L, CDK6,
BTG1 and SMAD3 were assayed, to evaluate whether any
of these genes was regulated in a similarly opposing
fashion. Retinoic acid and androgen treatment changed
CDCA7L and CDK6 expression in opposite directions
similar to the effect of these hormones on hTGP expres-
sion (Figure 7A and B). CDCA7L expression was
down-regulated by R1881 and stimulated by atRA,
Figure 6. Localization of the RAR and AR-binding sites and functional analysis of the hTGP promoter. (A) Position and names of the primer pairs
used for ChIP analysis of the hTGP promoter. (B) Binding of the RAR and AR to the hTGp promoter in LNCaP cells treated with vehicle.
(C) RAR and AR binding to the hTGP promoter 10h after 500nM atRA treatment. (D) RAR and AR binding to the hTGP promoter 10h after
10nM R1881 treatment. Binding of the receptors in all conditions was determined by ChIP–qPCR analysis. (E) Diagram depicting the constructs
used to analyse the role of each independent responsive element in the regulation of the hTGP promoter. The white crosses illustrate the responsive
element that was modiﬁed in each construct to down-regulate receptor binding. (F) Relative luciferase activity in LNCaP cells transfected with the
wild-type 4.5kb hTGP and responsive element mutants following vehicle, 500nM atRA or 10nM R1881 treatment. Statistically signiﬁcant T-test
differences between vehicle and treatments are denoted with the asterisk symbol, while differences between WT and mutant are denoted with the
symbol **(P<0.05).
Nucleic Acids Research, 2012,Vol.40, No. 11 4835Figure 7. Analysis of other genes potentially regulated by androgen and retinoic acid. CDCA7L (A), CDK6 (B), BTG1 (C) and SMAD3 (D) were
analysed for RAR and AR binding (upper panels) in selected RARE and ARE regions (middle panels). Gene expression was measured following
R1881 or atRA treatment to analyse the effect of these hormones on the expression of selected genes (bottom panels). Statistically signiﬁcant t-test
differences in receptor binding between IgG control and AR or RAR antibodies and treatments are denoted with the asterisk symbol (P<0.05).
Statistically signiﬁcant t-test differences in gene expression between vehicle and R1881 or atRA treatments are denoted with the asterisk symbol
(P<0.05).
4836 Nucleic Acids Research, 2012,Vol.40, No. 11whereas CDK6 expression was up-regulated by R1881
and suppressed by atRA.
In the case of BTG1 and SMAD3, both hormones
affected gene expression but did not have opposing
effects. BTG1 was up-regulated by atRA and R1881
while SMAD3 expression decreased after atRA and
R1881 treatment.
These experiments veriﬁed that, while not all genes
regulated by RAR and AR behaved similarly to hTGP,
some of them respond in opposing ways following atRA
and R1881 treatment, like hTGP. This demonstrates that
RAR and AR opposition could be a broad mechanism for
the regulation of gene expression in the prostate.
The cellular functions regulated by RAR and AR, were
determined by gene ontology analysis on AR and RAR
regulated genes to obtain statistically signiﬁcant (P<0.01)
enriched biological processes. Genes directly regulated by
both AR and RAR were implicated in metabolism,
apoptosis, gene expression, transcription and cell cycle
(Table 1 and Supplementary Table S2).
Since the short distance ( 150bp) between the active
ARE and the distal RARE in the hTGP promoter could
be an important feature in the regulation of this gene it
was decided to evaluate whether the distance between
reported AREs and putative RAREs, in genes which
presented both binding sites, could play a role in the regu-
lation of these genes. For this purpose, genes were classi-
ﬁed in two groups: (i) genes with at least one ARE and one
RARE spaced by <500bp and (ii) genes with all AREs
and RAREs spaced by >500bp. The proportion of genes
where AREs and RAREs are closely spaced is 19.17%
(Supplementary Table S1). This ﬁnding suggests that in
some genes the distance between ARE and RARE, and
possibly AR–RAR interaction, could play an important
role in their regulation, in a similar fashion as the
regulatory network controlling hTGP expression.
DISCUSSION
Prostate speciﬁc genes such as PSA, PSMA and NKX3.1
are mainly regulated by androgen and the AR, which has
led to the assumption that androgen regulation is neces-
sary and sufﬁcient for prostate speciﬁc gene expression
(23,24,47). hTGP expression is highly prostate speciﬁc,
even when compared to the expression proﬁle of the
archetypal prostate gene PSA (Figure 1). However, the
previously reported role of androgen in hTGP regulation
is reminiscent of an indirect regulation (21), since (i) no
canonical AREs were found in the proximal promoter and
(ii) the androgen stimulation was carried out over ten days
in contrast to most direct AR stimulations, which require
only 24h treatment. The presence of putative AREs and
RAREs within the extended hTGP promoter we describe
here, suggested a direct role for androgen and atRA
in hTGP, regulation, as both compounds play a critical
role in prostate development and differentiation
(13,14,46,48). However, our data indicates that atRA
played the major role in the regulation of hTGP expres-
sion in both luminally-differentiated prostate cancer cell
lines LNCaP and PC346C, while the benign and basal cell
lines PNT1A and PNT2C2 showed little response to atRA
treatment (Figure 2B). Absence of response to atRA
treatment was not due to lack of RAR expression
(Figure 2C and D), but could be explained by the differ-
ential ability of each cell line to sustain atRA-dependent
gene expression (Figure 2E). The observation that more
luminal-like cell lines are principally capable of sustaining
RAR-dependent gene activation could be related to the
role of atRA and RAR in promoting and maintaining
differentiation. This explanation is also in accordance
with hTGP protein expression, which was found only in
the luminal compartment of the prostate gland (49).
Androgen was previously shown to have a positive
effect on hTGP expression in PC346C cells, but not in
LNCaP, and only over a period of 10 days’ treatment
(21). Most AR-mediated transcriptional regulation
results in expression changes detectable within 24h of
steroid exposure. For hTGP, data describing a more
rapid and physiological response to androgen was
therefore lacking. Treatment of LNCaP and PC346C
cells with R1881 for a 24h period actually resulted in a
small decrease in hTGP mRNA levels. Thus the effect of
androgen was to antagonize that of atRA on hTGP
expression (Figure 3B). Antagonistic effects of androgen
and atRA have been previously described in both the pros-
tate, where the activity of the AR was down-regulated,
and expression of the PSA gene was negatively affected
after atRA treatment (39,50,51) and in lacrimal gland cells
(52). Interestingly, AR receptor knockdown showed that
AR was positively regulating hTGP transcription in
the absence of androgens (Figures 3D and 4A) and that
this positive regulation was not via up-regulation of the
RARs (Figure 4B). Using bicalutamide to block the AR
transcriptional activity, while keeping its DNA-binding
afﬁnity for AREs, did not signiﬁcantly decrease
(P<0.05) hTGP transcription (Figure 4C) and immuno-
ﬂuorescence localization (Figure 4D) and conﬁrmed
previous reports (43) that atRA does not interact with
the AR. Therefore, while the presence of AR is important
for normal hTGP expression, the regulation it exerts on
the hTGP gene does not depend on its transcriptional
transactivation activity, contrary to the classical
androgen–AR gene regulation. One possibility is that,
in the absence of androgen, the AR is cooperatively inter-
acting with the RAR to promote hTGP transcription,
while in the presence of androgen, AR activity would
change to promote transcriptional repression. This
Table 1. Selected GO enriched biological processes in genes with
RAR and AR binding
Term P-value GO ID
Negative regulation of metabolic process 0.000194017 GO:0009892
Regulation of cellular metabolic process 0.000197994 GO:0031323
Apoptotic cell clearance 0.000263505 GO:0043277
Negative regulation of gene expression 0.000301381 GO:0010629
Negative regulation of transcription 0.000644451 GO:0016481
Regulation of cell cycle 0.000853133 GO:0051726
Examples of enriched biological processes determined by gene ontology
analysis in genes that showed RAR and AR binding.
Nucleic Acids Research, 2012,Vol.40, No. 11 4837hypothesis is supported by the binding pattern of AR to
the hTGP promoter (Figure 6D) where atRA treatment
appears to maintain AR binding only in the region
adjacent to the RARE where the RAR is bound. Such
an interaction between the two nuclear receptors would
explain why the low levels of AR affect not only basal
hTGP transcription but also atRA-induced hTGP expres-
sion (Figure 7). A similar phenomenon has been recently
described in breast cancer, where the oestrogen receptor a
(ER-A) cooperates with the RAR-A to promote transcrip-
tion of a subset of ER responsive genes in the absence
of retinoic acid. Here, the binding of the RAR-A was
dependent on the presence of the ER and both proteins
can be found in the same transcription complexes,
although no direct interaction between the receptors
was proven (35).
The primary role of RAR in hTGP transcriptional
activation was conﬁrmed by treatment of cells with the
RAR-speciﬁc ligand TTNPB (Figure 5A), and when
coupled with the knockdown of RAR-B and RAR-G
(Figure 5B), the major role for RAR-G in RA-dependent
hTGP expression was demonstrated.
Previously, basal activity of the hTGP promoter was
mapped to the  113 to  61bp relative to the transcrip-
tional start site, and no functional ARE was found within
the  13 to  2077 region (29). We here show by functional
hTGP promoter analysis that a region in the distal
promoter was responsible for an increase in transcrip-
tional activity in the absence of treatment (Supplementary
Figure S1B). Remarkably, both an ARE and RARE were
located in the enhancer region and were responsive to
atRA and R1881 treatments, while other ARE and
RARE which mapped outside this 1kb enhancer region
( 4.5 to  3.5kb) did not show a positive effect on gene
expression (Supplementary Figure S1C and D). These
results suggest that the 4.5-kb region of the hTGP
promoter contains enough information to re-create the
in vivo gene regulation in an in vitro model. Deletion of
RAREs and ARE indicated the role of each site in the
regulation of hTGP expression. Similar enhancer regions
containing binding elements, such as AREs, have been
described to control the prostate speciﬁc genes PSA and
PSMA (22,24,53,54).
ChIP analysis conﬁrmed that RAR binding was in
close proximity to the predicted RAREs (Figure 6A).
The RAR-binding pattern did not change when cells
were treated with atRA or R1881, in accordance with
the existing model, where RAR is bound to the RARE
in the absence of ligand (7,8,55). Interestingly, the RARE
proximal to the transcription start site was occupied by
the RAR even after demonstration that the deletion of this
site has a positive effect on promoter activity after
atRA treatment (Figure 6C and F).
AR binding followed a similar pattern to that of RAR
in untreated cells, but was up-regulated by androgen treat-
ment in a region ( 4015 to  3909) adjacent to an ARE.
Thus AR binding to the distal hTGP promoter could
antagonize RAR activity by sterically preventing the re-
cruitment of co-activators or by actively recruiting
co-repressors to the promoter.
Moreover, the binding of AR and RAR to a speciﬁc set
of genes suggested the existence of a wide-spread regula-
tory mechanism. The validation of AR and RAR binding
to key genes in cell cycle, proliferation and transcriptional
control demonstrated that RAR and AR are capable
of together regulating a broad spectrum of genes.
Interestingly, hTGP is not the only gene where retinoic
acid and androgen have opposing effects. CDCA7L and
CDK6 also show a similar pattern, being up-regulated by
one hormone and down-regulated by the other. These
ﬁndings help to explain previous evidence of antagonistic
effects of these hormones. For example, the opposite
effects of androgen and retinoic acid in cell death are
well documented (56–59). In our analysis, genes important
for apoptosis have been shown to be regulated by AR and
RAR, consistent with a model in which AR and RAR
regulate cell death-related genes in an opposite manner.
A similar regulatory network has recently been described
in breast cancer for the RAR-A and the ER, where
binding sites for these receptors in a given gene exerted
antagonizing effects on its transcription (35,36). The
antagonistic co-regulation of AR and RAR activity,
which is related to the presence of androgen and RA,
could now play a role in prostate differentiation and
cancer as well.
In human prostate, cancer tissues have been shown to
contain less RA than normal tissues (60), while epidemio-
logical studies revealed an inverse relationship between
vitamin A, a precursor of RA, levels in serum and
prostate cancer incidence (61–63). Since RA can inhibit
growth and tumorigenic potential (59,64), it is likely that,
as a natural mechanism, while androgen signalling
promotes survival and growth in the prostate, RA
signalling could be used to regulate growth and survival,
and that a malfunction in the RA regulation could
contribute to prostate cancer as previously suggested (65).
These data provide the ﬁrst description of a
prostate-speciﬁc gene where androgen plays a minor role
in transcriptional regulation, raising the question of
whether the classical transcriptional role of androgen–
AR is sufﬁcient as a mechanism to achieve prostate-
speciﬁc expression. It also shows that RA might play an
important role not only in prostate development but
also in its function as a matured organ. Controlling the
expression of prostatic genes and antagonizing the
effects of androgen is important and perhaps necessary
to control prostate gland homeostasis. By investigating
how expression of the hTGP gene is restricted to the
prostate, in comparison to PSA and other androgen
regulated prostate speciﬁc genes, the role of RA in
gene expression patterns of individual cell types and the
binding pattern of RAR in human prostate will provide
a valuable insight into the complex regulation of
prostate development and differentiation as well as
prostate cancer.
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